Striatal signaling in L-DOPA-induced dyskinesia: common mechanisms with drug abuse and long term memory involving D1 dopamine receptor stimulation

Striatal signaling in L-DOPA-induced dyskinesia: common mechanisms with drug abuse and long term memory involving D1 dopamine receptor stimulation

Parkinson’s disease is a common neurodegenerative disorder caused by the degeneration of midbrain substantia nigra dopaminergic neurons that project to the striatum. Despite extensive investigation aimed at finding new therapeutic approaches, the dopamine precursor molecule, 3,4-dihydroxyphenyl-L-al...

Full description

Bibliographic Details
Main Authors:	Mario Gustavo Murer, Rosario eMoratalla
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2011-08-01
Series:	Frontiers in Neuroanatomy
Subjects:	Parkinson’s disease D1 dopamine receptor in dyskinesias D2 dopamine receptor in dyskinesias FosB-expression in denervated striatum Histone 3 phosphorylation in dyskinesias L-DOPA-induced dyskinesia
Online Access:	http://journal.frontiersin.org/Journal/10.3389/fnana.2011.00051/full

Similar Items

In vivo evidence of D3 dopamine receptor sensitization in parkinsonian primates and rodents with l-DOPA-induced dyskinesias
by: Rosario Sánchez-Pernaute, et al.
Published: (2007-08-01)

Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson’s disease
by: Yunmin Ding, et al.
Published: (2007-07-01)

The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation
by: Eunju Shin, et al.
Published: (2014-02-01)

Dopamine D3 Receptor Plasticity in Parkinson’s Disease and L-DOPA-Induced Dyskinesia
by: Kathryn Lanza, et al.
Published: (2021-03-01)

Nicotine-mediated improvement in l-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function
by: Maryka Quik, et al.
Published: (2013-02-01)

Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease
by: Eunju Shin, et al.
Published: (2012-09-01)

5-Hydroxy-tryptophan for the treatment of l-DOPA-induced dyskinesia in the rat Parkinson's disease model
by: Elisabetta Tronci, et al.
Published: (2013-12-01)

Serotonin system implication in L-DOPA-induced dyskinesia: from animal models to clinical investigations
by: Manolo eCarta, et al.
Published: (2014-05-01)

Focal not widespread grafts induce novel dyskinetic behavior in parkinsonian rats
by: Eleonora Maries, et al.
Published: (2006-01-01)

Regulation of dopamine neurotransmission from serotonergic neurons by ectopic expression of the dopamine D2 autoreceptor blocks levodopa-induced dyskinesia
by: Rhyomi C. Sellnow, et al.
Published: (2019-01-01)

In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to l-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels
by: Flora Mela, et al.
Published: (2012-01-01)

Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease
by: Chiara Fiorentini, et al.
Published: (2013-06-01)

Role of the atypical vesicular glutamate transporter VGLUT3 in l-DOPA-induced dyskinesia
by: Giuseppe Gangarossa, et al.
Published: (2016-03-01)

Dysfunction in the nigrostriatal system : effects of L-DOPA and GDNF
by: Nevalainen, Nina
Published: (2013)

Transcriptome analysis in a rat model of l-DOPA-induced dyskinesia
by: Christine Konradi, et al.
Published: (2004-11-01)

Effects of pulsatile l-DOPA treatment in the double lesion rat model of striatonigral degeneration (multiple system atrophy)
by: N Stefanova, et al.
Published: (2004-04-01)

Tardive dyskinesia in patients treated with atypical antipsychotics: case series and brief review of etiologic and treatment considerations
by: Jungjin Kim, et al.
Published: (2014-04-01)

Intrastriatal inhibition of aromatic amino acid decarboxylase prevents l-DOPA-induced dyskinesia: A bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats
by: Kerstin Buck, et al.
Published: (2008-02-01)

ATP Signaling Controlling Dyskinesia Through P2X7 Receptors
by: Analu A. Fonteles, et al.
Published: (2020-08-01)

Effects of L-dopa priming on cortical high beta and high gamma oscillatory activity in a rodent model of Parkinson's disease
by: Kristin B. Dupre, et al.
Published: (2016-02-01)

Beneficial effects of the phytocannabinoid Δ9-THCV in L-DOPA-induced dyskinesia in Parkinson's disease
by: Isabel Espadas, et al.
Published: (2020-07-01)

Effects and molecular mechanism of chitosan-coated levodopa nanoliposomes on behavior of dyskinesia rats
by: Xuebing Cao, et al.

Paroxysmal Dyskinesias
by: J Gordon Millichap
Published: (2003-09-01)

Rare form of dyskinetic movements associated with alcohol withdrawal
by: Sathya Prakash, et al.
Published: (2016-01-01)

Neuroinflammation in the generation of post-transplantation dyskinesia in Parkinson's disease
by: E.L. Lane, et al.
Published: (2008-11-01)

A first‐in‐human oral dose study of mesdopetam (IRL790) to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers
by: Folke Sjöberg, et al.
Published: (2021-05-01)

Immediate-early gene expression in structures outside the basal ganglia is associated to l-DOPA-induced dyskinesia
by: Matthieu F. Bastide, et al.
Published: (2014-02-01)

Probable respiratory dyskinesia in an elderly patient after sudden stoppage of antipsychotics
by: Vikram Vaidya, et al.
Published: (2016-01-01)

Pathophysiological Mechanisms and Experimental Pharmacotherapy for L-Dopa-Induced Dyskinesia
by: Fabbrini A, et al.
Published: (2021-04-01)

Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat
by: Manon Lebel, et al.
Published: (2010-04-01)

Tardive Dyskinesia-like Syndrome Due to Drugs that do not Block Dopamine Receptors: Rare or Non-existent: Literature Review
by: Anelyssa D'Abreu, et al.
Published: (2018-09-01)

D1 dopamine receptor stimulation impairs striatal proteasome activity in Parkinsonism through 26S proteasome disassembly
by: Pedro Barroso-Chinea, et al.
Published: (2015-06-01)

Interactions Between the Serotonergic and Other Neurotransmitter Systems in the Basal Ganglia: Role in Parkinson’s Disease and Adverse Effects of L-DOPA
by: Ana Muñoz, et al.
Published: (2020-06-01)

Correlación entre la expresión del receptor dopaminérgico D2 y presencia de movimientos involuntarios anormales (MIA) en un modelo de disquinesia en ratas Wistar hemiparkinsonizadas
by: P.A. Caro Aponte, et al.
Published: (2021-04-01)

Dyskinesias occur in response to saline and naltrexone alone after priming with combination of dopaminergic agents and naltrexone in the MPTP parkinsonian monkeys
by: Pershia Samadi, et al.
Published: (2005-06-01)

On dopamine neurons : nerve fiber outgrowth and L-DOPA effects
by: af Bjerkén, Sara
Published: (2008)

Severity of Dyskinesia and D3R Signaling Changes Induced by L-DOPA Treatment of Hemiparkinsonian Rats Are Features Inherent to the Treated Subjects
by: Sacnité Albarrán-Bravo, et al.
Published: (2019-09-01)

Corrigendum: Advances in non-dopaminergic pharmacological treatments of Parkinson’s disease
by: Sandy eStayte, et al.
Published: (2014-08-01)

Advances in non-dopaminergic pharmacological treatments of Parkinson's disease
by: Sandy eStayte, et al.
Published: (2014-05-01)

Drug-induced tardive dyskinesia
by: T. M. Ostroumova, et al.
Published: (2020-02-01)